In December 2025, GP2 announced the 11th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 20,842 additional genotyped participants, 17,153 additional WGS participants, and 4,232 additional clinical exomes. The genotype array (NBA) data, including locally-restricted samples, now consists of a total of 103,786 genotyped participants (46,327 PD cases, 28,857 Controls, and 28,602 ‘Other’ phenotypes). The whole genome sequencing (WGS) data now consists of a total of 38,226 sequenced participants (18,219 PD cases, 9,172 Controls, and 10,835 ‘Other’ phenotypes). The clinical exome data now consists of 14,648 samples with PD. Of the 122,317 unique samples with genetic data (NBA, WGS, or clinical exome), 32,897 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.17753486, release 11) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."